Roche is Denmark's second best mid-sized workplace

Roche is the second best mid-sized workplace in Denmark 2018. This is according to an analysis from the consultancy firm Great Place to Work. And for the twelfth year in a row, the Danish unit of the drug group takes a place in top 5.

Roche is Denmark's second-best workplace 2018, according to Great Place to Work. | Foto: Roche, PR

The working day begins well for the 130 employees in the Danish unit of Swiss drug group Roche Pharmaceuticals.

This is according to the consultancy- and analysis firm Great Place to Work that has ranked 135 Danish companies based on an evaluation of the workplace culture and an anonymous survey among 31,000 employees in total.

Roche ranks second as Denmark's best workplace in the category of companies with 50-499 staff members. Thereby, the company takes a step up from last year's third place and also becomes the best-ranking drug group.

We continuously work to develop the workplace and improve where the results are not at their peak.

Linda Vestergaard, HR Manager, Roche Denmark

Only the Danish IT firm Elbek & Vejrup surpassed Roche when the country's best workplaces were awarded in Copenhagen this week.

According to Linda Vestergaard, HR Manager at Roche Denmark, the top ranking reflects a determined effort.

"We continuously work to develop the workplace and improve where the results are not at their peak. Last year, we saw a slight reduction of the trust in the management. Obviously, we react to that, and during the past year we have taken initiatives to ensure a higher degree of credibility," she says in a press release from Roche.

The efforts seem to pay off, and Great Place to Work's survey show an improvement in the management's trustworthiness.

"Our staff members dare to state their opinion, and it enables us to continuously adjust and improve whatever needs to be developed. We are very pleased that the employees benefit from this effort, and this year's survey show an improvement in this field," says Vestergaard.

Abbvie must settle for third place

This year's ranking places Roche in top 5 for twelfth year in a row. And like in the past years, Roche scores a high level of staff satisfaction.

Liselotte Jensen, Managing Director in Great Place to Work Denmark, points out Roche's ability to include the employees as part of the explanation why the drug group moves from the  third to second place.

"Generally, job satisfaction has high priority at Roche, and it has been this way for many years. They are super good at keeping the staff informed and generally including the employees in what happens at the workplace. For that reason, they rank higher this year," says Jensen to MedWatch.

Generally, job satisfaction has high priority at Roche, and it has been this way for many years.

Liselotte Jensen, Managing Director, Great Place to Work Denmark

89 mid-sized companies participated in the Danish survey, and the third-best, Abbvie, is the only other pharmaceutical company in top 5.

In 2017, Abbvie took the prize as Denmark's best workplace but this year, the company had to settle with a third place. However, Jensen stresses that the lower ranking does not mean that Abbvie has become a worse place to work.

"Few decimals separate the top 3 rankings. Abbvie is still a good workplace - this year, there are just two other companies that improved their score with a couple of points. So, it is rather the others that have improved than Abbvie that has become worse," shes says.

In the category of large companies, the logistics company DHL Express & Aviation took the first place, while Absalon Hotel Group became the best small workplace 2018.

English Edit: Ida Løjmand

Would you like to receive the latest news from MedWatch directly in your e-mail inbox? Sign up for our free English newsletter below.

Mere fra MedWatch

Sydbank-analytiker: Positivt at Bavarian Nordic-aktiesalg klares hurtigt

Det er positivt, vurderer analytiker i Sydbank, at Bavarian Nordic allerede om en uge regner med at kunne præsentere resultatet af det udbud, selskabet tidligere mandag offentliggjorde, som skal sikre finansiering af et fase 3-studie med en vaccinekandidat mod RS-virus i første halvår 2022.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier